Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 1/20 | 0.47 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | FDPS | P14324 | 8/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9081590 | 0.98 | ANPEP (0.50) | ANPEPERAP2MAPTCA12CA1 | |
| SCHEMBL8597910 | 0.77 | ANPEP (0.61) | ANPEPERAP2MAPTCA12CA1 | |
| SCHEMBL8675612 | 0.76 | ANPEP (0.64) | ANPEPERAP2MAPTCA12CA1 | |
| SCHEMBL8991677 | 0.76 | ANPEP (0.64) | ANPEPERAP2MAPTCA12CA1 | |
| SCHEMBL9451579 | 0.74 | ANPEP (0.47) | ANPEPERAP2MAPTCA12CA1 | |
| SCHEMBL8843433 | 0.72 | CA12 (0.40) | ANPEPERAP2MAPTCA12CA1 | |
| SCHEMBL9160362 | 0.71 | ANPEP (0.38) | ANPEPERAP2MAPTCA12CA1 | |
| SCHEMBL8842734 | 0.71 | CA12 (0.41) | ANPEPERAP2MAPTCA12CA1 | |
| Hydrochloric Acid SCHEMBL25311139 | 0.71 | MAPT (0.52) | ANPEPERAP2MAPTCA12CA1 | |
| SCHEMBL9709649 | 0.71 | HRH3 (0.48) | ANPEPERAP2MAPTCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2150258-A2 | IMPROVED METHODS OF USING PHOSPHOANTIGENS TOGETHER WITH INTERLEUKIN-2 FOR THE TREATMENT OF CANCER | Innate Pharma S.A. (FR) | 2010-02-10 | — | — | EP | disclosed |
| US-20090202572-A1 | COMPOSITIONS AND METHODS FOR MODULATING BONE MASS | BAYLOR COLLEGE OF MEDICINE | 2009-08-13 | — | — | US | disclosed |
| WO-2008146167-A2 | IMPROVED METHODS OF USING PHOSPHOANTIGENS TOGETHER WITH INTERLEUKIN-2 FOR THE TREATMENT OF CANCER | INNATE PHARMA S.A. (FR) | 2008-12-04 | — | — | WO | disclosed |
| WO-2006102674-A2 | DIPHENYLHETEROCYCLE CHOLESTEROL ABSORPTION INHIBITORS | MICROBIA, INC. (US) | 2006-09-28 | — | — | WO | disclosed |
| US-5728650-A | Herbicidal aza bisphosphonic acids and compositions containing the same | ZENECA LIMITED (GB) | 1998-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090202572-A1 | COMPOSITIONS AND METHODS FOR MODULATING BONE MASS | ADRB2, ADRA2A, ADRB1 | ANPEP 1618/4885ERAP2 1300/4885MAPT 3969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.